Anthropometric, Metabolic, and Endocrine Parameters as Predictors of Estimated Average Glucose and Other Biomarkers of Dysglycemia in Women with Different Phenotypes of Polycystic Ovary Syndrome

Abstract

The aim of the study was to evaluate the efficacy of anthropometric, metabolic, and endocrine abnormalities as predictors of estimated average glucose and other biomarkers of dysglycemia in women with different phenotypes of polycystic ovary syndrome (PCOS). This cross-sectional study included 648 women with PCOS and 330 controls. A single protocol of investigation was applied for all subjects. PCOS women were divided by phenotypes according to the Rotterdam criteria. Biomarkers of dysglycemia were considered dependent variables and anthropometric, lipid, and hormone alterations as independent variables using univariate and multivariate logistic regressions. Univariate logistic regression analysis, controlled for age and BMI, showed that many biomarkers of dysglycemia could be predicted by anthropometric, lipid, and endocrine variables. Multivariate logistic models showed that in non-PCOS women estimated average glucose (eAG) was predicted by lower TSH levels (OR=0.39; p=0.045); fasting glucose was predicted by increased T (OR=2.3). For PCOS, phenotype A, eAG was predicted by decreased HDL-C (OR=0.17, p=0.023) and high levels of free estradiol (OR=7.1, p<0.001). Otherwise, in PCOS, phenotype D, eAG was predicted by higher levels of HDL-C. The current study demonstrated that eAG was poorly predicted by anthropometric, lipid, and hormone parameters. Nevertheless, without adding significant benefits, it was comparable with other established markers of dysglycemia in women with different PCOS phenotypes.

Key words

polycystic ovary syndrome - biomarkers - androgens - insulin resistance - dyslipidemia

Publication History

Received: 25 July 2023

Accepted after revision: 07 November 2023

Accepted Manuscript online:
08 November 2023

Article published online:
10 January 2024

• References

• 1 The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25
• 2 March WA, Moore VM, Willson KJ. et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010; 25: 544-551
• 3 Ding T, Hardiman PJ, Petersen I. et al. The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: a systematic review and meta-analysis. Oncotarget 2017; 8: 96351-96358
• 4 Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif AG, Haseltine F (eds). Polycystic ovary syndrome. Baston: Blackwall Scientific; 1992: 377-384
• 5 Azziz R, Carmina E, Dewailly D. et al. and Task force on the phenotype of the polycystic ovary syndrome of the androgen excess and PCOS society. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009; 91: 456-488
• 6 Spritzer PM, Marchesan LB, Santos BR. et al. and Brazilian PCOS Network. Prevalence and characteristics of polycystic ovary syndrome in Brazilian women: protocol for a nation-wide case-control study. BMJ Open 2019; 9: e029191
• 7 Wild RA, Rizzo M, Clifton S. et al. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril 2011; 95: 1073-1079.e11
• 8 Spritzer PM, Ramos RB, Marchesan LB. et al. Metabolic profile of women with PCOS in Brazil: a systematic review and meta-analysis. Diabetol Metab Syndr 2021; 13: 18
• 9 Mellembakken JR, Mahmoudan A, Mørkrid L. et al. Higher blood pressure in normal weight women with PCOS compared to controls. Endocr Connect 2021; 10: 154-1563
• 10 Long C, Feng H, Duan W. et al. Prevalence of polycystic ovary syndrome in patients with type 2 diabetes: a systematic review and meta-analysis. Front Endocrinol 2022; 31: 980405
• 11 Zhu T, Cui J, Goodarzi MO. Polycystic ovary syndrome and risk of type 2 diabetes, coronary heart disease, and 014stroke. Diabetes 2021; 70: 627-637
• 12 Carmina E, Azziz R. Diagnosis, phenotype, and prevalence of polycystic ovary syndrome. Fertil Steril 2006; 86: S7-S8
• 13 de Medeiros SF, Yamamoto MMW, Souto de Medeiros MA. et al. Changes in clinical and biochemical characteristics of polycystic ovary syndrome with advancing age. Endocr Connect 2020; 9: 74-89
• 14 Dadachanji R, Patil A, Joshi B. et al. Elucidating the impact of obesity on hormonal and metabolic perturbations in polycystic ovary syndrome phenotypes in Indian women. PLoS One 2021; 16: e0246862
• 15 Cassar S, Misso ML, Hopkins WG. et al. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod 2016; 31: 2619-2631
• 16 Sakaguchi K, Takeda K, Maeda M. et al. Glucose area under the curve during oral glucose tolerance test as an index of glucose intolerance. Diabetol Int 2016; 7: 53-58
• 17 Amisi CA. Markers of insulin resistance in Polycystic ovary syndrome women: An update. World J Diabetes 2022; 13: 129-149
• 18 Nathan DM, Turgeon H, Regan S. Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia 2007; 50: 2239-2244
• 19 Nathan DM, Kuenen J, Borg R. et al. A1c-Derived average glucose study group. translating the A1C assay into estimated average glucose values. Diabetes Care 2008; 31: 1473-1478
• 20 de Medeiros SF, Barbosa JS, Yamamoto MM. Comparison of steroidogenic pathways among normoandrogenic and hyperandrogenic polycystic ovary syndrome patients and normal cycling women. J Obstet Gynaecol Res 2015; 41: 254-263
• 21 de Medeiros SF, Yamamoto MMW, de-Medeiros MAS. et al. Should subclinical hypothyroidism be an exclusion criterion for the diagnosis of polycystic ovary syndrome?. J Reprod Infertil 2017; 18: 242-250
• 22 New MI, Lorenzen F, Lerner AJ. et al. Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J Clin Endocrinol Metab 1983; 57: 320-326
• 23 Matthews DR, Hosker JP, Rudenski AS. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
• 24 Amato MC, Giordano C. Visceral adiposity index: an indicator of adipose tissue dysfunction. Int J Endocrinol. 2014
• 25 Wehr E, Gruber HJ, Giuliani A. et al. The lipid accumulation product is associated with impaired glucose tolerance in PCOS women. J Clin Endocrinol Metab 2011; 96: E986-E990
• 26 Sachdeva G, Gainder S, Suri V. et al. Comparison of the different PCOS phenotypes based on clinical metabolic, and hormonal profile, and their response to clomiphene. Indian J Endocrinol Metab 2019; 23: 326-331
• 27 Jamil AS, Alalaf SK, Al-Tawil NG. et al. A case-control observational study of insulin resistance and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on Rotterdam criteria. Reprod Health 2015; 12: 7
• 28 Gupta M, Radhakrishnan G, Madhu SV. et al. Comparison of metabolic and endocrinol parameters in obese and nonobese women of polycystic ovarian syndrome with normal controls. Fertil Sci Res 2015; 2: 19-23
• 29 Shroff R, Syrop CH, Davis W. et al. Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria. Fertil Steril 2007; 88: 1389-1395
• 30 Kim MJ, Lim NK, Choi YM. et al. Prevalence of metabolic syndrome is higher among non-obese PCOS women with hyperandrogenism and menstrual irregularity in Korea. PLoS One 2014; 9: e99252
• 31 Ram N, Ahmed S, Sattar S. et al. Relationship between estimated average glucose (eAG) and fasting plasma glucose in a cohort of Pakistani diabetic subjects. Cureus 2021; 13: e18435
• 32 Tang X, Yan X, Zhou H. et al. Associations of insulin resistance and beta-cell function with abnormal lipid profile in newly diagnosed diabetes. Chin Med J (Engl) 2022; 135: 2554-2562
• 33 Ciampelli M, Leoni F, Cucinelli F. et al. Assessment of insulin sensitivity from measurements in the fasting state and during an oral glucose tolerance test in polycystic ovary syndrome and menopausal patients. J Clin Endocrinol Metab 2005; 90: 1398-1406
• 34 Göbl CS, Ott J, Bozkurt L. et al. To assess the association between glucose metabolism and ectopic lipid content in different clinical classifications of PCOS. PLoS One 2016; 11: e0160571
• 35 Luque-Ramírez M, Alpañés M, Escobar-Morreale HF. The determinants of insulin sensitivity, β-cell function, and glucose tolerance are different in patients with polycystic ovary syndrome than in women who do not have hyperandrogenism. Fertil Steril 2010; 94: 2214-2221